January 15, 2017

 

Happy New Year from ProLung!

2016 has been a spectacular year.

To achieve our research goals more rapidly, we assembled the most extensive team of clinical investigators of lung cancer in pulmonology.

This speeds the clinical evaluation required for FDA market approval, sets the stage for rapid commercial rollout, insurance reimbursement and commercial growth. The quality of the physician investigators in the US and in Europe is beyond what we could have imagined at this point last year.  These clinics, now active in ProLung’s pivotal trial, have choices in what to research.  As shareholders, we are deeply grateful for each clinic’s commitment.  Today, lung cancer remains the leading cause of cancer death for men and women.  With the help from these champion clinicians, a better pathway is just around the corner.   2016 brought the golden age of pulmonology.  Here are the clinics that are bringing ProLung and their patients into that age by participating in ProLung research or offering the ProLung test to patients (Europe):

Azienda Ospedaliera Universitaria San Martino di Genova (pulmonology)
Azienda Ospedaliera Universitaria San Martino di Genova (thoracic surgery)
Azienda Ospedaliero Universitaria Maggiore della Carità di Novara
Azienda Ospedaliero Universitaria Careggi
Chicago Chest Center Interventional Pulmonology and Thoracic Disease
Greater Baltimore Medical Center
Harvard University at Beth Israel Deaconess Hospital
Henry Ford Hospital
Huntsman Cancer Institute at the University of Utah
Intermountain Healthcare
Johns Hopkins School of Medicine
Loyola University, Providence Health Center
Lungenklinik Löwenstein
M D Anderson Cancer Center
Medical University of South Carolina
Northwestern Memorial Hospital
Stanford Healthcare
Università Politecnica della Marche
Universitätsspital Basel
University of California at Los Angeles (pulmonology)
University of California at Los Angeles (radiology)
University of California at San Diego
University of Geneva
University of Minnesota […]